GW Pharmaceuticals announces Sativex regulatory approval in Switzerland GW Pharmaceuticals announced that it has received regulatory approval for its prescription medicine Sativex in Switzerland. A full marketing authorization has been granted by the Swissmedic authorities in the treatment of moderate to severe spasticity in Multiple Sclerosis patients who have not responded adequately to other anti-spasticity medications. Launch timing is dependent on completion of pricing and reimbursement procedures. Sativex will be commercialized in Switzerland by GW's European partner, Almirall S.A.
News For GWPH From The Last 14 Days
Check below for free stories on GWPH the last two weeks.
GW Pharmaceuticals breaks out to new session high, levels to watch Shares have broken out above the prior high for the session at $68.45, which is now support. At the current price of $69.17, next resistance is at $71.01.